BONANNI FABRIZIO 4

4 · AMGEN INC · Filed Jul 31, 2012

Insider Transaction Report

Form 4

Period: 2012-07-27

AMGEN INCAMGN

BONANNI FABRIZIO

EVP, Operations

Transactions

Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−84,000→ 0 total
Exercise: $42.13From: 2009-04-29Exp: 2015-04-29→ Common Stock (84,000 underlying)
Exercise/Conversion
Common Stock
2012-07-27$42.13/sh+84,000$3,538,920→ 271,510 total
Exercise/Conversion
Common Stock
2012-07-27$50.44/sh+63,000$3,177,720→ 334,510 total
Exercise/Conversion
Common Stock
2012-07-27$58.43/sh+42,000$2,454,060→ 376,510 total
Gift
Common Stock
2012-07-27+303,011→ 363,639 total(indirect: By Trust)
Exercise/Conversion
Common Stock
2012-07-27$71.88/sh+42,109$3,026,795→ 115,608 total
Exercise/Conversion
Common Stock
2012-07-27$56.79/sh+30,000$1,703,700→ 187,510 total
Sale
Common Stock
2012-07-30$84.33/sh−12,137$1,023,562→ 48,491 total(indirect: By Trust)
Exercise/Conversion
Common Stock
2012-07-27$62.55/sh+41,902$2,620,970→ 157,510 total
Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−41,902→ 0 total
Exercise: $62.55From: 2008-04-26Exp: 2014-04-26→ Common Stock (41,902 underlying)
Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−42,000→ 42,000 total
Exercise: $58.43From: 2011-04-26Exp: 2020-04-26→ Common Stock (42,000 underlying)
Gift
Common Stock
2012-07-27−303,011→ 73,499 total
Sale
Common Stock
2012-07-27$82.14/sh−303,011$24,888,718→ 60,628 total(indirect: By Trust)
Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−42,109→ 0 total
Exercise: $71.88From: 2007-04-03Exp: 2013-04-03→ Common Stock (42,109 underlying)
Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−30,000→ 0 total
Exercise: $56.79From: 2008-10-29Exp: 2014-10-29→ Common Stock (30,000 underlying)
Exercise/Conversion
Nqso (Right to Buy)
2012-07-27−63,000→ 21,000 total
Exercise: $50.44From: 2010-04-28Exp: 2016-04-28→ Common Stock (63,000 underlying)

Footnotes (5)

[F1]These shares are being transferred to the reporting person's Family Trust.
[F2]These shares include the following Restricted Stock Units (RSUs) granted under the Company's equity plans: 3,000 RSUs which fully vest on 4/28/2013; 6,000 RSUs which vest in two equal annual installments of 3,000 each commencing 4/26/2013; 40,000 RSUs which vest fully on 12/31/2013; 15,800 RSUs which vest in two equal installments of 5,214 each on 4/25/2013 and 4/25/2014 and one installment of 5,372 on 4/25/2015; and 8,654 RSUs which vest in three installments of 2,855, 2,856 and 2,943 on 4/27/2014, 4/27/2015 and 4/27/2016, respectively. Vested RSUs will be paid in shares of the Company's common stock on a one-to-one basis.
[F3]These shares include 45 Dividend Equivalents (DEs) granted pursuant to the Amgen Inc. 2009 Equity Incentive Plan and subject to a qualifying dividend reinvestment plan. DEs are credited on the reporting person's unvested RSUs and are paid out in shares of the Company's common stock on a one-to-one basis according to the vesting schedule, along with a cash payment for any remaining fractional share amount.
[F4]The price reported is an average price. The prices ranged from $81.56 to $82.48 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.
[F5]The price reported is an average price. The prices ranged from $84.32 to $84.37 per share. Full information regarding the number of shares sold at each separate price within the range set forth above is available upon request by the SEC staff, the issuer or a security holder of the issuer.

Documents

1 file

4
form4.xmlPrimary
PRIMARY DOCUMENT